183 related articles for article (PubMed ID: 38508444)
1. HSPA9/mortalin inhibition disrupts erythroid maturation through a TP53-dependent mechanism in human CD34+ hematopoietic progenitor cells.
Butler C; Dunmire M; Choi J; Szalai G; Johnson A; Lei W; Chen X; Liu L; Li W; Walter MJ; Liu T
Cell Stress Chaperones; 2024 Apr; 29(2):300-311. PubMed ID: 38508444
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of HSPA9 induces TP53-dependent apoptosis in human hematopoietic progenitor cells.
Liu T; Krysiak K; Shirai CL; Kim S; Shao J; Ndonwi M; Walter MJ
PLoS One; 2017; 12(2):e0170470. PubMed ID: 28178280
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of Hspa9, a del(5q31.2) gene, results in a decrease in hematopoietic progenitors in mice.
Chen TH; Kambal A; Krysiak K; Walshauser MA; Raju G; Tibbitts JF; Walter MJ
Blood; 2011 Feb; 117(5):1530-9. PubMed ID: 21123823
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial Hspa9/Mortalin regulates erythroid differentiation via iron-sulfur cluster assembly.
Shan Y; Cortopassi G
Mitochondrion; 2016 Jan; 26():94-103. PubMed ID: 26702583
[TBL] [Abstract][Full Text] [Related]
5. TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.
Caceres G; McGraw K; Yip BH; Pellagatti A; Johnson J; Zhang L; Liu K; Zhang LM; Fulp WJ; Lee JH; Al Ali NH; Basiorka A; Smith LJ; Daugherty FJ; Littleton N; Wells RA; Sokol L; Wei S; Komrokji RS; Boultwood J; List AF
Proc Natl Acad Sci U S A; 2013 Oct; 110(40):16127-32. PubMed ID: 24043769
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of p53 provides a competitive advantage to del(5q) myelodysplastic syndrome hematopoietic stem cells during inflammation.
Muto T; Walker CS; Agarwal P; Vick E; Sampson A; Choi K; Niederkorn M; Ishikawa C; Hueneman K; Varney M; Starczynowski DT
Haematologica; 2023 Oct; 108(10):2715-2729. PubMed ID: 37102608
[TBL] [Abstract][Full Text] [Related]
7. TP53 status regulates ACSL5-induced expression of mitochondrial mortalin in enterocytes and colorectal adenocarcinomas.
Klaus C; Kaemmerer E; Reinartz A; Schneider U; Plum P; Jeon MK; Hose J; Hartmann F; Schnölzer M; Wagner N; Kopitz J; Gassler N
Cell Tissue Res; 2014 Jul; 357(1):267-78. PubMed ID: 24770931
[TBL] [Abstract][Full Text] [Related]
8. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells.
Dutt S; Narla A; Lin K; Mullally A; Abayasekara N; Megerdichian C; Wilson FH; Currie T; Khanna-Gupta A; Berliner N; Kutok JL; Ebert BL
Blood; 2011 Mar; 117(9):2567-76. PubMed ID: 21068437
[TBL] [Abstract][Full Text] [Related]
9. Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9.
Schneider RK; Schenone M; Ferreira MV; Kramann R; Joyce CE; Hartigan C; Beier F; Brümmendorf TH; Germing U; Platzbecker U; Büsche G; Knüchel R; Chen MC; Waters CS; Chen E; Chu LP; Novina CD; Lindsley RC; Carr SA; Ebert BL
Nat Med; 2016 Mar; 22(3):288-97. PubMed ID: 26878232
[TBL] [Abstract][Full Text] [Related]
10. Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?
Gorshein E; Weber UM; Gore S
Expert Rev Hematol; 2020 Mar; 13(3):233-239. PubMed ID: 32067540
[No Abstract] [Full Text] [Related]
11. Molecular pathogenesis of myelodysplastic syndromes with deletion 5q.
Lee JH; List A; Sallman DA
Eur J Haematol; 2019 Mar; 102(3):203-209. PubMed ID: 30578738
[TBL] [Abstract][Full Text] [Related]
12. Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.
Chesnais V; Arcangeli ML; Delette C; Rousseau A; Guermouche H; Lefevre C; Bondu S; Diop M; Cheok M; Chapuis N; Legros L; Raynaud S; Willems L; Bouscary D; Lauret E; Bernard OA; Kosmider O; Pflumio F; Fontenay M
Blood; 2017 Jan; 129(4):484-496. PubMed ID: 27856460
[TBL] [Abstract][Full Text] [Related]
13. GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes.
Maratheftis CI; Bolaraki PE; Voulgarelis M
Am J Hematol; 2007 Oct; 82(10):887-92. PubMed ID: 17570514
[TBL] [Abstract][Full Text] [Related]
14. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.
Gaballa MR; Besa EC
Ann Hematol; 2014 May; 93(5):723-33. PubMed ID: 24627193
[TBL] [Abstract][Full Text] [Related]
15. Reduced levels of Hspa9 attenuate Stat5 activation in mouse B cells.
Krysiak K; Tibbitts JF; Shao J; Liu T; Ndonwi M; Walter MJ
Exp Hematol; 2015 Apr; 43(4):319-30.e10. PubMed ID: 25550197
[TBL] [Abstract][Full Text] [Related]
16. Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells.
Starenki D; Hong SK; Lloyd RV; Park JI
Oncogene; 2015 Aug; 34(35):4624-34. PubMed ID: 25435367
[TBL] [Abstract][Full Text] [Related]
17. The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes.
McGraw KL; Zhang LM; Rollison DE; Basiorka AA; Fulp W; Rawal B; Jerez A; Billingsley DL; Lin HY; Kurtin SE; Yoder S; Zhang Y; Guinta K; Mallo M; Solé F; Calasanz MJ; Cervera J; Such E; González T; Nevill TJ; Haferlach T; Smith AE; Kulasekararaj A; Mufti G; Karsan A; Maciejewski JP; Sokol L; Epling-Burnette PK; Wei S; List AF
Blood Cancer J; 2015 Mar; 5(3):e291. PubMed ID: 25768405
[TBL] [Abstract][Full Text] [Related]
18. Restoration of p53 functions by suppression of mortalin-p53 sequestration: an emerging target in cancer therapy.
Shankaranarayana AH; Meduri B; Pujar GV; Hariharapura RC; Sethu AK; Singh M; Bidye D
Future Med Chem; 2023 Nov; 15(22):2087-2112. PubMed ID: 37877348
[TBL] [Abstract][Full Text] [Related]
19. Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.
Ximeri M; Galanopoulos A; Klaus M; Parcharidou A; Giannikou K; Psyllaki M; Symeonidis A; Pappa V; Kartasis Z; Liapi D; Hatzimichael E; Kokoris S; Korkolopoulou P; Sambani C; Pontikoglou C; Papadaki HA;
Haematologica; 2010 Mar; 95(3):406-14. PubMed ID: 19773257
[TBL] [Abstract][Full Text] [Related]
20. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level.
Nilsson L; Astrand-Grundström I; Arvidsson I; Jacobsson B; Hellström-Lindberg E; Hast R; Jacobsen SE
Blood; 2000 Sep; 96(6):2012-21. PubMed ID: 10979941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
